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OBJECTIVE: The study purpose was to determine the re-
lationship between pain severity and sumatriptan and
OTC medication use for migraine attack treatment.
METHODS: This study was part of a larger 6-month,
prospective, observational study evaluating migraine-
related outcomes in migraineurs within a managed care
organization (MCO). The MCO is a mixed staff and in-
dependent practice association model. Enrolled patients
were those who received their first prescription for
sumatriptan and had been a member of the MCO for at
least 6 months. Pain severity was self-recorded by pa-
tients as mild, moderate, or severe when each dose of
medication was taken during the attack.
RESULTS: A total of 168 patients reported 1,304 mi-
graine attacks with an average of 1.3 attacks/member!
month. Of the 1,304 attacks, 32% were mild, 43% were
moderate, and 25% were severe at the time the first mi-
graine medication was taken. Sumatriptan was used in
82% of migraine attacks. Patients were more likely to use
sumatriptan during severe migraine attacks (86%) than
in mild attacks (79%) (p < 0.05). Patients were more
likely to use OTC medications during mild attacks (55%)
than in severe attacks (20%) (p < 0.05). Patients who
took sumatriptan as the first medication during an attack
took fewer medication doses (2.4) than in attacks where
sumatriptan was used as a second or subsequent dose
(4.7) (p < 0.05).
CONCLUSION: This observational study shows that mi-
graineurs in managed care tend to use OTC medications
for mild migraine attacks and sumatriptan for severe at-
tacks. Additional studies should be performed to evaluate
the clinical and cost outcomes of this effect and to develop
migraine medication treatment protocols to encourage ap-
propriate treatment and management of migraine.
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Previous studies of antidepressants in clinical practice
have established a link between initial antidepressant se-
lection and patterns of antidepressant use and health care
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expenditures. However, there has been far less research
to date demonstrating a link between the patterns of anti-
depressant use and patients' clinical outcomes using data
from actual clinical practice.
OBJECTIVE: The purpose of this study using data from
a clinical practice setting was to test whether the pattern
of antidepressant use was correlated with patients' treat-
ment response as measured by the score on the Clinical
Global Impressions-Improvement scale.
DATA AND METHODS: A dataset of patients who initi-
ated therapy on one the most common selective serotonin
reuptake inhibitors (SSRIs) fluoxetine, fluvoxamine, par-
oxetine, or sertraline in a general practitioner setting in
Spain was used. A Cox proportional hazard analysis was
used to predict the likelihood of treatment response based
upon the pattern of initial antidepressant use, while con-
trolling for the influence of other baseline characteristics.
RESULTS: After controlling for other observed baseline
characteristics including initial disease severity, patients
who remained on their initial antidepressant therapy for
at least two months with no switching, augmentation, or
upward dose titration were 63.2% more likely (p < 0.05)
than patients who had an adjustment to therapy to expe-
rience a treatment response.
CONCLUSION: The pattern of antidepressant use is an
important determinant of treatment response among pa-
tients initiating therapy on the newer antidepressants in
clinical practice.
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Study of the duration and pattern of antidepressant use in
the naturalistic setting can provide important insights
into how antidepressant use patterns compare to recom-
mended depression treatment guidelines. The World
Health Organization and consensus groups in the United
Kingdom have, for example, established depression treat-
ment guidelines recommending at least four to nine
months of antidepressant therapy beyond initial symp-
tom resolution for depressive episodes. In light of the in-
creased use of selective serotonin reuptake inhibitors
(SSRIs), it is reasonable to evaluate whether differences
exist among individual SSRIs in their use relative to
guidelines.
OBJECTIVE: The purpose of this study was to assess the
effects of initial SSRI antidepressant selection on the sub-
sequent pattern and duration of antidepressant use across
drug types in actual clinical practice in the United States,
among patients who had an indicator of a depression-
related diagnosis on their insurance claims forms and
were given an initial drug selection.
METHODS AND DATA: Logistic regression analysis of
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data from a large general practitioner medical records da-
tabase (DINLINK) for the years 1992-1997 was used to
estimate the determinants of antidepressant drug use pat-
terns for 6,007 patients with a "new" episode of anti-
depressant therapy who were prescribed one of three most
often prescribed SSRIs: paroxetine, sertraline, or fluoxe-
tine. Using an insurance claims database, we study antide-
pressant use patterns over a twelve month follow-up pe-
riod for individual patients described as having depression
and who initiated pharmacotherapy on tricyclic antide-
pressants, or the SSRIs sertraline, paroxetine, or fluoxetine
in an outpatient setting in the United States between 1990
. and 1994.
RESULTS: Patients who initiated therapy on sertraline or
paroxetine were less likely than patients who initiated
therapy on fluoxetine to have four or more 30-day pre-
scriptions of their initial antidepressant within the first
six months. The magnitude of these differences was
greater for patients who initiated SSRI therapy between
1995 and 1997, as compared to 1992 through 1994.
CONCLUSION: There is increasing evidence that antide-
pressant use patterns differ across TCAs and individual
SSRIs in the actual clinical practice setting. The findings
suggest that the particular SSRI selected is an important
determinant of use consistent with current recommended
depression treatment guidelines in primary care in the
United Kingdom.
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This study analyzed antidepressant utilization and de-
pression diagnoses among patients who initiated antide-
pressant therapy in mid-1995 through a national man-
aged care organization (MCa) and its behavioral health
component.
OBJECTIVE: The purpose of this study was to evaluate
antidepressant usage in 31 managed care plans nation-
wide as part of a national quality assurance program to
understand and improve utilization of antidepressants
and the overall quality of care provided to patients.
METHODS: A retrospective analysis was conducted us-
ing prescription, diagnoses, and eligibility databases of
the national Mca and its behavioral health component.
Adults who were continuously eligible for medical and
pharmacy benefits during the study period and received
one or more prescriptions for one of 20 antidepressants
during April 1, 1995 through August 31,1995 were con-
sidered for selection. Duration of therapy, titration, and
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switching/augmentation patterns were evaluated in the
nine months following therapy initiation.
RESULTS: The cross-sectional analysis revealed that 77%
of all antidepressant prescriptions were written by primary
care providers, and 58% of all antidepressant prescriptions
did not have a primary or secondary depression diagnosis.
SSRIs were clearly the drug of choice and had a more sus-
tained length of treatment, but average days of continuous
therapy did not meet AHCPR guidelines of minimum du-
ration (i.e., four months). Switching was most frequent for
those patients who failed a TCA or trazodone.
CONCLUSION: As a result of these findings, the man-
aged care organization's behavioral health component
implemented intervention measures aimed at improving
care by physicians. Due to the success of this collabora-
tive effort, additional studies between the MCa, its be-
havioral health component, and PCS are under way.
